Specific type of gut bacteria are major contributors to lymphoma, a cancer of the white blood cells that are part of the human immune system, say researchers. The study, led by Robert Schiestl, member of the JCCC and professor of pathology and laboratory medicine, environmental health sciences, and radiation oncology, was published online ahead of press today in the journal Cancer Research.
In rodents, intestinal bacteria influence obesity, intestinal inflammation, and certain types of epithelial cancers. Those cancers affect the coverings of the stomach, liver or colon. However, little is known about the identity of the bacterial species that promote the growth of or protect the body from cancer, or about their effect on lymphoma.
Up to 1,000 different species of bacteria (intestinal microbiota) live in the human gut. Intestinal microbiota number 100 trillion cells; over 90% of the cells in the body are bacteria. The composition of each person's microbiome- the body's bacterial make-up - is very different, due to the original childhood source of bacteria, and the effects of diet and lifestyle.
Schiestl's group wanted to determine whether differences in peoples' microbiomes affect their risk for lymphoma, and whether changing the bacteria can reduce this risk. They studied mice with ataxia-telangiectasia (A-T), a genetic disease that in humans and mice is associated with a high rate of B-cell lymphoma. They discovered that, of mice with A-T, those with certain microbial species lived much longer than those with other bacteria before developing lymphoma, and had less of the gene damage (genotoxicity) that causes lymphoma.
"This study is the first to show a relationship between intestinal microbiota and the onset of lymphoma," Schiestl said. "Given that intestinal microbiota is a potentially modifiable trait, these results hold considerable promise for intervention of B cell lymphoma and other diseases."
The scientists were also able to create a detailed catalog of bacteria types with promoting or protective effects on genotoxicity lymphoma, which could be used in the future to create combined therapies that kill the bacteria that promote cancer (such as antibiotics) and expand the bacteria that protect from cancer (such as probiotics).
This work was supported by the National Institutes of Health (NIH), JCCC, the Crohn's and Colitis Foundation of America, the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, the Austrian Federal Ministry of Science and Research, NASA, University of California Toxic Substances Research and Teaching Program, and the UCLA Graduate Division.
UCLA's Jonsson Comprehensive Cancer Center has more than 240 researchers and clinicians engaged in disease research, prevention, detection, control, treatment and education. One of the nation's largest comprehensive cancer centers, the Jonsson center is dedicated to promoting research and translating basic science into leading-edge clinical studies. In July 2012, the Jonsson Cancer Center was once again named among the nation's top 10 cancer centers by U.S. News & World Report, a ranking it has held for 12 of the last 13 years. For more information on the Jonsson Cancer Center, visit our website at http://www.cancer.ucla.edu.